Meeting
2022 ASCO Genitourinary Cancers Symposium
Impact of primary tumor location on efficacy and safety of pembrolizumab (pembro) in patients (pts) with locally advanced or metastatic urothelial carcinoma (UC) enrolled in the phase 2 KEYNOTE-052 and phase 3 KEYNOTE-045 trials.
Authors
Peter H. O'Donnell
The University of Chicago, Chicago, IL
Peter H. O'Donnell , Arjun Vasant Balar , Daniel E. Castellano , Ronald De Wit , David J. Vaughn , Thomas Powles , Jacqueline Vuky , Jae-Lyun Lee , Yves Fradet , Joaquim Bellmunt , Lawrence Fong , Daniel P. Petrylak , Winald R. Gerritsen , David I. Quinn , Stephane Culine , Dean F. Bajorin , Jin Zhi Xu , Kentaro Imai , Blanca Homet Moreno , Petros Grivas
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Urothelial Carcinoma
Track
Urothelial Carcinoma
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT02256436 and NCT02335424
Citation
J Clin Oncol 40, 2022 (suppl 6; abstr 516)
DOI
10.1200/JCO.2022.40.6_suppl.516
Abstract #
516
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A phase 2 study of magrolimab combination therapy in patients with recurrent or metastatic head and neck squamous cell carcinoma: ELEVATE HNSCC.
First Author: A. Dimitrios Dimitrios Colevas
Poster
2019 Genitourinary Cancers Symposium
EV-301: Phase III study to evaluate enfortumab vedotin (EV) versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial cancer (la/mUC).
First Author: Daniel Peter Petrylak
Poster
2018 ASCO Annual Meeting
Pembrolizumab (pembro) versus investigator’s choice (paclitaxel, docetaxel, or vinflunine) in recurrent, advanced urothelial cancer (UC): 2-year follow-up from the phase 3 KEYNOTE-045 trial.
First Author: Yves Fradet
